Lyfegen

Are you still relying on outdated methods for pricing and market access processes? It’s time for a change. 𝗟𝘆𝗳𝗲𝗴𝗲𝗻’𝘀 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿 is the tool designed to keep your Market Access and Pricing teams ahead of the curve. With growing pricing pressures and the need for faster decisions, this simulator 𝗲𝗺𝗽𝗼𝘄𝗲𝗿𝘀 𝘆𝗼𝘂 𝘁𝗼 𝗺𝗮𝗸𝗲 𝗱𝗮𝘁𝗮-𝗱𝗿𝗶𝘃𝗲𝗻 𝗰𝗵𝗼𝗶𝗰𝗲𝘀 and 𝗻𝗮𝘃𝗶𝗴𝗮𝘁𝗲 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲𝘀 with confidence. 💡 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁𝗹𝘆 𝗺𝗼𝗱𝗲𝗹 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀: Quickly build and test various drug rebate contracts to understand their impact on your gross-to-net revenue and costs. 🤝 𝗣𝘂𝗿𝗽𝗼𝘀𝗲-𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Move beyond Excel with a platform tailored for Market Access and Pricing teams, enabling seamless collaboration across different markets and assets. ⚡ 𝗦𝗽𝗲𝗲𝗱 𝘂𝗽 𝘆𝗼𝘂𝗿 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀: Respond to market changes faster and create better rebate agreements that meet the demands of an evolving landscape. Watch the video where our CEO breaks down how this innovative tool can transform your approach to drug pricing and negotiations. Don’t wait—pricing pressures are rising, and the need for smarter, faster decisions is now. Stay ahead, 𝗯𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗱𝗲𝗺𝗼 with us today: https://hubs.la/Q02PjHrb0 #pharma #marketaccess #drugpricing #negotiation #healthcare #pricingstrategy #Lyfegen #LyfegenSimulator #PricingModels

𝗪𝗲’𝗿𝗲 𝗼𝗻 𝗮 𝗥𝗼𝗹𝗹: 𝗧𝗵𝗲 𝗟𝘆𝗳𝗲𝗴𝗲𝗻 𝗟𝗶𝗯𝗿𝗮𝗿𝘆 𝗡𝗼𝘄 𝗛𝗮𝘀 𝟲,𝟬𝟬𝟬+ 𝗣𝘂𝗯𝗹𝗶𝗰 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀! 🚀 Our 𝗹𝗶𝗯𝗿𝗮𝗿𝘆 𝗸𝗲𝗲𝗽𝘀 𝗴𝗿𝗼𝘄𝗶𝗻𝗴, and your access just got 6,000x smarter! We’ve now surpassed 𝟲,𝟬𝟬𝟬 𝗽𝘂𝗯𝗹𝗶𝗰 𝗱𝗿𝘂𝗴 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗸𝗲𝘆 𝗺𝗮𝗿𝗸𝗲𝘁𝘀, with major contributions from China and Brazil in full coverage. Plus, we’ve added updates from Switzerland, Denmark, the Netherlands, Finland, Australia, Italy, and Germany, along with ongoing updates for other countries. 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁—𝘁𝗵𝗶𝘀 𝗶𝘀 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱’𝘀 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝗣𝘂𝗯𝗹𝗶𝗰 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗟𝗶𝗯𝗿𝗮𝗿𝘆, empowering you to discover, learn, and plan like never before. See how Lyfegen can help you accelerate access, enhance affordability, and save time & money. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲—𝗮𝗰𝘁 𝗻𝗼𝘄 𝗮𝗻𝗱 𝗯𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗱𝗲𝗺𝗼 𝘁𝗼𝗱𝗮𝘆: https://hubs.la/Q02PhgbK0 #Lyfegen #HealthcareInnovation #RebateManagement #MarketAccess #ValueBasedHealthcare #PharmaceuticalPricing #HealthcareTechnology #DrugRebateSolutions #DigitalHealthcare #LyfegenLibrary #PatientOutcomes #RevenueOptimization

🚨 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀-𝗕𝗮𝘀𝗲𝗱 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗪𝗲𝗶𝗴𝗵𝘁 𝗟𝗼𝘀𝘀 𝗗𝗿𝘂𝗴𝘀: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗡𝗲𝗲𝗱 𝘁𝗼 𝗞𝗻𝗼𝘄 🚨 As GLP-1 therapies such as Wegovy and Zepbound continue to gain momentum, payers are exploring strategies to balance patient access with rising costs. Here are 𝟯 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: 𝟭. 𝗦𝘂𝗿𝗴𝗶𝗻𝗴 𝗗𝗲𝗺𝗮𝗻𝗱 𝗮𝗻𝗱 𝗥𝗶𝘀𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀: GLP-1 drug spending is projected to grow by 378% by 2027, intensifying the need for effective cost management strategies. 𝟮. 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗨𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆: Payers are cautious about covering these therapies, exploring outcomes-based agreements to mitigate financial risks. 𝟯. 𝗣𝗿𝗼𝘃𝗲𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: GLP-1 therapies not only assist with weight loss but also reduce cardiovascular risks, underscoring the need for strategic pricing. In this evolving landscape, Lyfegen offers 𝘁𝘄𝗼 𝗽𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝘁𝗼𝗼𝗹𝘀 to help Market Access and Pricing teams make smarter decisions: 💡 𝗟𝘆𝗳𝗲𝗴𝗲𝗻 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿: • Efficiently model pricing scenarios and simulate the impact on gross-to-net revenue and costs. • Collaborative, purpose-built rebate agreements that allow for faster, better decisions. • Streamline contracting by comparing various models, giving you the agility needed to respond to pricing pressures. 📚 𝗟𝘆𝗳𝗲𝗴𝗲𝗻 𝗟𝗶𝗯𝗿𝗮𝗿𝘆: • Searchable database of drug pricing models and public agreements. • Compare pricing strategies, analyze trends, and gain competitive intelligence for informed decision-making. • Search by countries, payers, and product types, enabling a comprehensive view of the market. ⚡ 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁 𝗼𝗻 𝘁𝗵𝗶𝘀 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝗮𝗻𝗱 𝗯𝗼𝗼𝗸 𝗮 𝗱𝗲𝗺𝗼 𝘁𝗼𝗱𝗮𝘆- Discover how Lyfegen can help you make smarter, faster decisions in drug contracting: https://hubs.la/Q02P4nXM0 #OutcomesBasedAgreements #GLP1Drugs #WeightLossDrugs #DrugPricing #MarketAccess #HealthEconomics #ValueBasedCare #LyfegenSimulator #LyfegenLibrary #DrugContracting #PayerStrategy #HealthcareCostManagement #PharmaTrends #PricingStrategy #PharmaInsights #Lyfegen #ClinicalOutcomes #PharmaSolutions

We’ve arrived at the Canada's Drug Agency Symposium 2024! Today and tomorrow, visit the Lyfegen team at booth #07—one of the leading health technology assessment conferences in the world. Discover how Lyfegen is revolutionizing PLA contracting and rebate management for provinces and manufacturers across Canada. Whether you’re attending in person or virtually, stop by our booth or connect with our team to learn how our innovative solutions are driving healthcare forward! Ina Hasani, MSc, MBA Simon Farrow Girisha Fernando Nico Julian Mros #CDA2024 #Lyfegen #CDA_AMC #OttawaEvents #PLAContracting #AccessPathways #PLAManagement #HealthcareEvents #RebateManagement

Next week, the Lyfegen team will be attending the Canada's Drug Agency Symposium 2024 in Ottawa, one of the leading health technology assessment conferences in the world. This 3-day hybrid event brings together leaders from across Canada, including experts in policy, industry, health technology assessment, patient advocacy, medicine, public health, and communications. We’re excited to showcase how Lyfegen is transforming PLA contracting and rebate management for both provinces and manufacturers within Canada. Discover how we are driving innovation in healthcare by booking a demo with us before the event here: https://hubs.la/Q02MGBl00 Attending the Symposium 2024 in Ottawa or online? Don’t miss the opportunity to connect with our team. Learn about our innovative solutions and discuss how we can work together—reach out to us today! Girisha Fernando Nico Julian Mros Ina Hasani, MSc, MBA Simon Farrow #CDA2024 #Lyfegen #CDA_AMC #OttawaEvents #PLAContracting #AccessPathways #PLAManagement #HealthcareEvents #RebateManagement

The ABPI recently released a report by Charles River Associates that explores the opportunities and challenges of 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 (𝗔𝗧𝗠𝗣𝘀) 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗞. While these therapies hold great promise, the report identifies key challenges such as 𝗵𝗶𝗴𝗵 𝘂𝗽𝗳𝗿𝗼𝗻𝘁 𝗰𝗼𝘀𝘁𝘀, 𝘂𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 𝗮𝗿𝗼𝘂𝗻𝗱 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀, and the 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘇𝗲𝗱 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲. To address these challenges, the report suggests several important strategies: • 𝗔𝗱𝗼𝗽𝘁 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗣𝗮𝘆𝗺𝗲𝗻𝘁 𝗠𝗼𝗱𝗲𝗹𝘀: Implement payment plans that are linked to treatment outcomes to better manage financial risks. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗲𝘅𝗮𝗺𝗽𝗹𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗟𝘆𝗳𝗲𝗴𝗲𝗻 𝗟𝗶𝗯𝗿𝗮𝗿𝘆 👉 https://hubs.la/Q02MvbFR0 • 𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻 𝗗𝗮𝘁𝗮 𝗜𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲: Develop a national platform to track patient outcomes, supporting the implementation of new payment models. • 𝗙𝗼𝘀𝘁𝗲𝗿 𝗘𝗮𝗿𝗹𝘆 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Start discussions with payers and manufacturers early to create innovative and practical contracts. 𝗟𝘆𝗳𝗲𝗴𝗲n has successfully implemented over 𝟯,𝟮𝟬𝟬 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀, including cutting-edge payment models. We provide the tools and insights needed to create better access agreements. Our solutions include the 𝘄𝗼𝗿𝗹𝗱’𝘀 𝗹𝗮𝗿𝗴𝗲𝘀𝘁 𝗹𝗶𝗯𝗿𝗮𝗿𝘆 𝗼𝗳 𝗽𝘂𝗯𝗹𝗶𝗰 𝗱𝗿𝘂𝗴 𝗮𝗰𝗰𝗲𝘀𝘀 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗼𝘂𝗿 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿. These resources ensure that your strategies are both informed and tested. Get started today by booking a demo with Lyfegen: https://hubs.la/Q02Mv9L60

𝗪𝗶𝘁𝗵 𝘁𝗵𝗲 𝗿𝗲𝗰𝗲𝗻𝘁 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗼𝗳 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗲𝗱 𝗽𝗿𝗶𝗰𝗲𝘀 𝘂𝗻𝗱𝗲𝗿 𝘁𝗵𝗲 𝗜𝗻𝗳𝗹𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗔𝗰𝘁, 𝘁𝗵𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗶𝘀 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝗿𝗮𝗽𝗶𝗱𝗹𝘆. Medicare has secured discounts of up to 𝟳𝟵% on key drugs, dramatically altering pricing dynamics. Are you ready for the upcoming changes to 𝗠𝗲𝗱𝗶𝗰𝗮𝗿𝗲 𝗣𝗮𝗿𝘁 𝗗 in 2025? Here are the key takeaways from our latest article: 1️⃣ The out-of-pocket spending cap drops to $𝟮,𝟬𝟬𝟬, shifting more costs to payers and drug makers. 2️⃣ Specialty drug makers, especially in oncology, face a 𝟮𝟬% 𝗱𝗶𝘀𝗰𝗼𝘂𝗻𝘁 during the catastrophic phase, potentially lasting most of the year. 3️⃣ Medicare Advantage plans will see their drug cost liability increase from 𝟮𝟬% 𝘁𝗼 𝟲𝟬%. With these shifts, the financial impact will be significant, making it crucial to adapt quickly. 𝗔𝗰𝘁 𝗻𝗼𝘄—𝗟𝘆𝗳𝗲𝗴𝗲𝗻’𝘀 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗼𝗿 is the tool you need to stay ahead of the curve: 📊 𝗠𝗼𝗱𝗲𝗹 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀: Quickly assess the impact on revenue and costs. 🤝 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀𝗹𝘆: Move beyond Excel with a purpose-built platform. ⚡ 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀: Adapt faster to new pricing pressures. 𝗧𝗵𝗲 𝘁𝗶𝗺𝗲 𝘁𝗼 𝗽𝗿𝗲𝗽𝗮𝗿𝗲 𝗶𝘀 𝗻𝗼𝘄. Don’t let these changes catch you off guard. 🔗 Read our full article below and 𝗯𝗼𝗼𝗸 𝗮 𝗱𝗲𝗺𝗼 𝘁𝗼𝗱𝗮𝘆 to discover how Lyfegen can support you: https://lnkd.in/dn6Nh7sh 

𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀: 𝗧𝗵𝗲 𝗟𝘆𝗳𝗲𝗴𝗲𝗻 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗟𝗶𝗯𝗿𝗮𝗿𝘆 𝗷𝘂𝘀𝘁 𝗴𝗼𝘁 𝗲𝘃𝗲𝗻 𝗯𝗶𝗴𝗴𝗲𝗿! 🚀 We’re now proud to have 5,500+ public agreements across 35+ countries we have scoped, with 110+ payers, 470+ manufacturers, and 1,500+ products. 🌍 Don’t miss out—this is the 𝘄𝗼𝗿𝗹𝗱’𝘀 𝗺𝗼𝘀𝘁 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 𝗟𝗶𝗯𝗿𝗮𝗿𝘆, empowering you to find, learn, and plan like never before. Discover how Lyfegen can help you 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗮𝗰𝗰𝗲𝘀𝘀, 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝘀𝗮𝘃𝗲 𝘁𝗶𝗺𝗲 & 𝗺𝗼𝗻𝗲𝘆. Explore the future—act now and 𝗯𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗱𝗲𝗺𝗼 𝘁𝗼𝗱𝗮𝘆! https://hubs.la/Q02LK4tG0 #Lyfegen #HealthcareInnovation #RebateManagement #MarketAccess #ValueBasedHealthcare #PharmaceuticalPricing #HealthcareTechnology #DrugRebateSolutions #DigitalHealthcare #HealthcareAffordability #PatientOutcomes #RevenueOptimization #ComplianceSolutions

The US Federal Government has revealed the final negotiated prices for the first 10 drugs under the Inflation Reduction Act, securing discounts of up to 𝟳𝟵% 𝗼𝗳𝗳 𝗹𝗶𝘀𝘁 𝗽𝗿𝗶𝗰𝗲𝘀. These new prices will come into effect in 2026, with an estimated $𝟲 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻 𝘀𝗮𝘃𝗶𝗻𝗴𝘀 for taxpayers and $𝟭.𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 in reduced out-of-pocket costs for patients. Here’s what this means for the pharmaceutical industry:  𝟭. 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗣𝗿𝗶𝗰𝗲 𝗥𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻𝘀: The negotiated prices are considerably lower than list prices, challenging companies to rethink their pricing strategies.  𝟮. 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗦𝗰𝗿𝘂𝘁𝗶𝗻𝘆 𝗼𝗻 𝗡𝗲𝘁 𝗣𝗿𝗶𝗰𝗲𝘀: With the focus on net savings, understanding the impact of rebates and discounts is now more critical.  𝟯. 𝗡𝗲𝘄 𝗗𝘆𝗻𝗮𝗺𝗶𝗰𝘀 𝗶𝗻 𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴: As these changes reshape the market, pharmaceutical companies must adapt quickly to remain competitive. As the pharmaceutical industry goes through these changes, it’s crucial to have the right tools in place. This is where Lyfegen comes into play with its cutting-edge solutions like the Drug Contracting Simulator, an innovative tool designed to help Market Access and Pricing teams stay ahead in this landscape: 💡 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁𝗹𝘆 𝗠𝗼𝗱𝗲𝗹 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗦𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀: Build and test a wide range of drug rebate contracts, allowing you to quickly assess the impact on gross-to-net revenue and costs. 🤝 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗮𝗻𝗱 𝗣𝘂𝗿𝗽𝗼𝘀𝗲-𝗕𝘂𝗶𝗹𝘁: Move away from Excel-based tools with our dedicated platform, designed for Market Access and Pricing teams, and re-usable across different markets and assets. ⚡ 𝗙𝗮𝘀𝘁𝗲𝗿, 𝗕𝗲𝘁𝘁𝗲𝗿 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀: Streamline the creation of rebate agreements in a collaborative environment, helping you respond more effectively to new pricing pressures. Don’t miss out on staying ahead in this new regulatory environment. Book a demo with us today: https://hubs.la/Q02LGKDY0 #PharmaPricing #MarketAccess #HealthcareInnovation #DrugPricing #Medicare #PharmaTech #HealthPolicy #Pharmaceuticals #PricingStrategy #HealthcareTransformation #HTA #InflationReductionAct #ValueBasedCare #RebateAgreements #DigitalHealth #Lyfegen

We’re excited to share insights from the Lyfegen Agreements Library about Brazil’s growing importance in Pharma launch strategies. Our preview covers key findings on Brazil’s Drug Access Agreements, including: 1. Agreements breakdown by therapeutic areas and pricing models 2. Highlighted featured agreements 3. Main manufacturers and the HTA process As Brazil becomes a key market for Pharma companies, our library offers essential information to help you enter this market efficiently and ahead of the competition. To learn more about Brazil’s Drug Access Agreements or get access to our library, book a demo with us today: https://hubs.la/Q02L4mzM0 #Healthcare #Pharma #HTA #Brazil #MedicalAgreements #PharmaIndustry #HealthTech #ANVISA #CONITEC #MedTech #HealthcareInnovation #MarketAccess #Lyfegen